Virginia R Barton MD FAAD

Dermatology•Scarborough, ME

Dermatologist

Join to View Full Profile

71 US Route 1Ste JScarborough, ME 04074
Phone+1 207-770-5621
Fax+1 207-203-4875

Summary

Dr. Virginia Barton is a Dermatologist based in Scarborough, ME, currently employed at Optima Dermatology. She completed her dermatology residency at Tulane University in 2024. Her professional journey includes positions at Tulane Medical Center, the Medical University of South Carolina, UC Davis Medical Center, and Prisma Health. She has contributed to the field through several publications in reputable dermatology journals, focusing on topics such as topical treatments, the impact of COVID-19 on medical supply chains, and managing dermatological conditions. Dr. Barton is also involved in clinical trials related to atopic dermatitis and other skin conditions.

Education & Training

Tulane UniversityResidency, Dermatology, 2021 - 2024
Medical University of South CarolinaClass of 2018
Prisma Health/University of South Carolina SOM Greenville (Greenville)Internship, Surgery

Certifications & Licensure

ME State Medical License 2024 - 2027
SC State Medical License 2018 - 2025
LA State Medical License 2021 - 2024
CA State Medical License 2019 - 2021
American Board of Dermatology Dermatology

Clinical Trials

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) Start of enrollment: 2017 Nov 30
Completed
Phase 2, Phase 3
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Start of enrollment: 2015 Oct 15
Active, not recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Start of enrollment: 2018 Sep 24
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Feb 20
Completed
Phase 3
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27
Terminated
Phase 3
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Start of enrollment: 2019 Dec 30
ACTIVE_NOT_RECRUITING
PHASE3
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2019 Jun 27
COMPLETED
PHASE3
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis Start of enrollment: 2019 May 01
Terminated
Phase 2
PRISM Study-Pruritus Relief Through Itch Scratch Modulation Start of enrollment: 2018 Aug 07
Completed
Phase 2, Phase 3
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Start of enrollment: 2020 Nov 17
Completed
Phase 3
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Start of enrollment: 2018 Dec 21
RECRUITING
Observational Evaluation of Atopic Dermatitis in Pediatric Patients Start of enrollment: 2019 Aug 15
RECRUITING
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY) Start of enrollment: 2019 Apr 05
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Start of enrollment: 2020 Mar 02
COMPLETED
PHASE3
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis Start of enrollment: 2018 Dec 19
COMPLETED
PHASE3
DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone Start of enrollment: 2020 Aug 24
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

16 citations
Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic Porokeratosis:...
Gabriella Santa Lucia, Alan Snyder, Almeera Lateef, Alex Drohan, Mathew J Gregoski
JAMA Dermatology. 2023-05-01
1 citations
Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study.
N Ezeh, K Ardalan, K A Buhr, C Nguyen, O Al Ahmed
Journal of the American Academy of Dermatology. 2022-09-01
Disruption of the Medical Supply Chain by the COVID-19 Pandemic Adversely Affecting Dermatologic Surgery.
Gage Rensch, Virginia Barton, Patrick Ragland
Dermatologic Surgery. 2022-04-01